{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:59Z","timestamp":1791500039150,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40257-024-00911-x","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T21:38:33Z","timestamp":1734471513000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4453-3234","authenticated-orcid":false,"given":"Jennifer","family":"Strong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia S.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"911_CR1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10:2094.","journal-title":"Cells"},{"key":"911_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.det.2015.07.002","volume":"34","author":"JR Ingram","year":"2016","unstructured":"Ingram JR. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016;34:23\u20138.","journal-title":"Dermatol Clin"},{"key":"911_CR3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2020.05.090","volume":"83","author":"S Wright","year":"2020","unstructured":"Wright S, Strunk A, Garg A. New-onset depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83:1360\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"911_CR4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatol Basel Switz. 2020;236:421\u201330.","journal-title":"Dermatol Basel Switz."},{"key":"911_CR5","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, Wolk K, Tsaousi A, Irmer ML, M\u00f6\u00dfner R, Shomroni O, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139:1294\u2013305.","journal-title":"J Invest Dermatol"},{"key":"911_CR6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","volume":"5","author":"A Cartron","year":"2019","unstructured":"Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5:330\u20134.","journal-title":"Int J Womens Dermatol."},{"key":"911_CR7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jid.2019.08.445","volume":"140","author":"HB Naik","year":"2020","unstructured":"Naik HB, Jo J-H, Paul M, Kong HH. Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa. J Invest Dermatol. 2020;140:922-925.e3.","journal-title":"J Invest Dermatol"},{"key":"911_CR8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20:525\u201345.","journal-title":"Expert Rev Clin Immunol"},{"key":"911_CR9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.13777","volume":"173","author":"G Shalom","year":"2015","unstructured":"Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464\u201370.","journal-title":"Br J Dermatol"},{"key":"911_CR10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jdv.17857","volume":"36","author":"R Kjaersgaard Andersen","year":"2022","unstructured":"Kjaersgaard Andersen R, Loft IC, Hansen T, Hjalgrim H, Rostgaard K, Banasik K, et al. Incidence and remission rates of self-reported hidradenitis suppurativa\u2014a prospective cohort study conducted in Danish blood donors. J Eur Acad Dermatol Venereol JEADV. 2022;36:717\u201325.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"911_CR11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jaad.2019.08.034","volume":"82","author":"A Balgobind","year":"2020","unstructured":"Balgobind A, Finelt N, Strunk A, Garg A. Association between obesity and hidradenitis suppurativa among children and adolescents: a population-based analysis in the United States. J Am Acad Dermatol. 2020;82:502\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"911_CR12","first-page":"437","volume":"19","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, Vanlaerhoven AMJD, Ardon CB, van der Zee HH. Body mass index at the onset of hidradenitis suppurativa. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2021;19:437\u20139.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG."},{"key":"911_CR13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjd.19713","volume":"185","author":"S Wright","year":"2021","unstructured":"Wright S, Strunk A, Garg A. Trends in body mass index before and after diagnosis of hidradenitis suppurativa. Br J Dermatol. 2021;185:74\u20139.","journal-title":"Br J Dermatol"},{"key":"911_CR14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bjd.13864","volume":"174","author":"V Bettoli","year":"2016","unstructured":"Bettoli V, Naldi L, Cazzaniga S, Zauli S, Atzori L, Borghi A, et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa\u2013acne inversa: evidence from the national Italian registry. Br J Dermatol. 2016;174:195\u20137.","journal-title":"Br J Dermatol"},{"key":"911_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831\u20139.","journal-title":"Br J Dermatol"},{"key":"911_CR16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/ijd.15910","volume":"61","author":"D Mintoff","year":"2022","unstructured":"Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175\u201386.","journal-title":"Int J Dermatol"},{"key":"911_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00403-021-02233-y","volume":"314","author":"PC Macklis","year":"2022","unstructured":"Macklis PC, Tyler K, Kaffenberger J, Kwatra S, Kaffenberger BH. Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. Arch Dermatol Res. 2022;314:293\u2013300.","journal-title":"Arch Dermatol Res"},{"key":"911_CR18","volume":"33","author":"JM Fernandez","year":"2020","unstructured":"Fernandez JM, Marr KD, Hendricks AJ, Price KN, Ludwig CM, Maarouf M, et al. Alleviating and exacerbating foods in hidradenitis suppurativa. Dermatol Ther. 2020;33: e14246.","journal-title":"Dermatol Ther"},{"key":"911_CR19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000532116","volume":"9","author":"V Long","year":"2023","unstructured":"Long V, Tham S-L, Choi EC-E, Chandran NS. Exercise recommendations for hidradenitis suppurativa patients. Skin Appendage Disord. 2023;9:392\u20136.","journal-title":"Skin Appendage Disord."},{"key":"911_CR20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jdv.19726","volume":"38","author":"K Bouwman","year":"2024","unstructured":"Bouwman K, Moazzen S, Kroah-Hartman M, Dijkstra G, Horv\u00e1th B, Alizadeh BZ. Diet and physical activity as risk-reducing factors for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38:910\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"911_CR21","doi-asserted-by":"crossref","unstructured":"Lorite-Fuentes I, Montero-Vilchez T, Arias-Santiago S, Molina-Leyva A. Potential benefits of the mediterranean diet and physical activity in patients with hidradenitis suppurativa: a cross-sectional study in a Spanish population. Nutrients. 2022;14:551.","DOI":"10.3390\/nu14030551"},{"key":"911_CR22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"C Kromann","year":"2014","unstructured":"Kromann C, Ibler KS, Kristiansen V, Jemec GBE. The Influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"24","key":"911_CR23","first-page":"00121","volume":"S1550\u20137289","author":"A Chierici","year":"2024","unstructured":"Chierici A, Bulsei J, Alromayan M, Alamri A, Pavone G, Fontas E, et al. Bariatric surgery reduces the incidence of hidradenitis suppurativa in individuals with obesity: results of a nationwide administrative data study in France. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2024;S1550\u20137289(24):00121\u20137.","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg."},{"key":"911_CR24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ced.13732","volume":"44","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, De Simone C, Giovanardi G, Robustelli E, Marzano AV, Peris K. Post-bariatric surgery hidradenitis suppurativa: a new patient subset associated with malabsorption and micronutritional deficiencies. Clin Exp Dermatol. 2019;44:283\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"911_CR25","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaad.2011.12.032","volume":"68","author":"E Javorsky","year":"2013","unstructured":"Javorsky E, Kimball AB. Hidradenitis suppurativa: patient experiences with bariatric surgery. J Am Acad Dermatol. 2013;68:AB89\u2013AB89.","journal-title":"J Am Acad Dermatol"},{"key":"911_CR26","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"911_CR27","unstructured":"Caffrey MK. Liraglutide approved under new name to treat obesity. Am J Manag Care [Internet]. 2015;21. Available from: https:\/\/www.ajmc.com\/view\/liraglutide-approved-under-new-name-to-treat-obesity."},{"key":"911_CR28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"911_CR29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443\u201351.","journal-title":"Int J Obes"},{"key":"911_CR30","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117\u201328.","journal-title":"N Engl J Med"},{"key":"911_CR31","unstructured":"FDA approves weight management drug for patients aged 12 and older [Internet]. US Food Drug Adm. 2020. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20has%20approved%20Saxenda%20(liraglutide,60%20kg%20(132%20pounds)."},{"key":"911_CR32","unstructured":"FDA approves new drug treatment for chronic weight management, first since 2014. US Food Drug Adm. 2021."},{"key":"911_CR33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obes Silver Spring Md. 2020;28:1050\u201361.","journal-title":"Obes Silver Spring Md."},{"key":"911_CR34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"911_CR35","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"911_CR36","unstructured":"FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. US Food Drug Adm. 2024."},{"key":"911_CR37","unstructured":"FDA approves new medication for chronic weight management [Internet]. US Food Drug Adm. 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management."},{"key":"911_CR38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"911_CR39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022;327:138\u201350.","journal-title":"JAMA"},{"key":"911_CR40","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"M-S Popoviciu","year":"2023","unstructured":"Popoviciu M-S, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023;24:10449.","journal-title":"Int J Mol Sci"},{"key":"911_CR41","unstructured":"Cubanski J, Neuman T, Sroczynski N, Damico A. A new use for Wegovy opens the door to medicare coverage for millions of people with obesity [Internet]. KFF. 2024 [cited 2024 Jul 27]. Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity\/#:~:text=Medicare%20is%20currently%20prohibited%20by,for%20diabetes%2C%20branded%20as%20Ozempic."},{"key":"911_CR42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","volume":"150","author":"X Xu","year":"2019","unstructured":"Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019;150:167\u201373.","journal-title":"Diabetes Res Clin Pract"},{"key":"911_CR43","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, Ye H, He X, Chen S, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatol Treat. 2022;33:1428\u201334.","journal-title":"J Dermatol Treat"},{"key":"911_CR44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern T, Tobin A-M, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol JEADV. 2013;27:1440\u20133.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"911_CR45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol. 2014;171:155\u201361.","journal-title":"Br J Dermatol"},{"key":"911_CR46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2013a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol JEADV. 2015;29:555\u20139.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"911_CR47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","volume":"161","author":"J Nicolau","year":"2023","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161:293\u20136.","journal-title":"Med Clin (Barc)"},{"key":"911_CR48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","volume":"177","author":"L Jennings","year":"2017","unstructured":"Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177:858\u20139.","journal-title":"Br J Dermatol"},{"key":"911_CR49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000473873","volume":"9","author":"BN Khandalavala","year":"2017","unstructured":"Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9:70\u20138.","journal-title":"Case Rep Dermatol"},{"key":"911_CR50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","volume":"162","author":"J Nicolau","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162:118\u201322.","journal-title":"Med Clin (Barc)"},{"key":"911_CR51","doi-asserted-by":"crossref","unstructured":"Lyons D, Louly Nathan A, Pender E, Murray G, Smith C, Kirby B, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191:631\u20133.","DOI":"10.1093\/bjd\/ljae216"},{"key":"911_CR52","doi-asserted-by":"crossref","unstructured":"Chan LJ, Kaur M, Kaffenberger B. A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide. JAAD Case Rep [Internet]. 2024. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624000833.","DOI":"10.1016\/j.jdcr.2024.02.023"},{"key":"911_CR53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36:130-143.e5.","journal-title":"Cell Metab"},{"key":"911_CR54","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.","journal-title":"Front Immunol"},{"key":"911_CR55","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaad.2023.07.359","volume":"89","author":"C Drumm","year":"2023","unstructured":"Drumm C, Clowry J, Healy M-L, Wynne B. 42762 Successful treatment of hidradenitis suppurativa with semaglutide. J Am Acad Dermatol. 2023;89:AB89.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00911-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:28:14Z","timestamp":1740367694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00911-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"2 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Consent was not required for this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"No ethics approval was required for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the literature review, preparation of the manuscript and review of the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}